Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin

GOTHENBURG, Sweden, Jan. 17, 2019 /PRNewswire/ — Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC)….

Source: https://www.prnewswire.com:443/news-releases/isofol-reports-early-tumor-shrinkage-in-patients-with-colorectal-cancer-in-phase-12a-open-label-extension-study-with-arfolitixorin-300780071.html